{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:30:38Z","timestamp":1793989838788,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12954-019-0298-2","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T14:04:24Z","timestamp":1554991464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-0699","authenticated-orcid":false,"given":"Andrew","family":"Scheibe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph L.","family":"Basson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Versfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Sonderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Prabdial-Sing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Manamela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Puren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hausler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"298_CR1","unstructured":"World Health Organization. Global hepatitis report, 2017. Geneva: WHO; 2017. Available from: \n                    https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf;jsessionid=47CAD7FA53D5A32ED4FC61E568F7E958?sequence=1\n                    \n                  ."},{"key":"298_CR2","volume-title":"Fact sheet\u2014world AIDS day 2018","author":"UNAIDS","year":"2018","unstructured":"UNAIDS. Fact sheet\u2014world AIDS day 2018. Geneva: UNAIDS; 2018."},{"issue":"4","key":"298_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ije\/dyr050","volume":"40","author":"S. Dalal","year":"2011","unstructured":"Dalal S, Beunza JJ, Volmink J, Adebamowo C, Bajunirwe F, Njelekela M, et al. Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol. 2011;40:885\u2013901. Available from: \n                    https:\/\/doi.org\/10.1093\/ije\/dyr050\n                    \n                  . [cited 2011 Aug 30].","journal-title":"International Journal of Epidemiology"},{"key":"298_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/S2468-1253(17)30295-9","volume":"2","author":"CW Spearman","year":"2017","unstructured":"Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol. 2017;2:2121 Available from: \n                    https:\/\/doi.org\/10.1016\/S2468-1253(17)30295-9\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"e1024","DOI":"10.1016\/j.ijid.2010.06.013","volume":"14","author":"RE Barth","year":"2010","unstructured":"Barth RE, Huijgen Q, Taljaard J, Hoepelman AIM. Hepatitis B\/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010;14:e1024\u201331 Available from: \n                    https:\/\/doi.org\/10.1016\/j.ijid.2010.06.013\n                    \n                  .","journal-title":"Int J Infect Dis"},{"key":"298_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcv.2014.05.018","volume":"61","author":"PC Matthews","year":"2014","unstructured":"Matthews PC, Maria A, Goulder PJR, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and Hepatitis C viruses in sub-Saharan Africa. J Clin Virol. 2014;61:20\u201333 Available from: \n                    https:\/\/doi.org\/10.1016\/j.jcv.2014.05.018\n                    \n                  .","journal-title":"J Clin Virol"},{"issue":"12","key":"298_CR7","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"Louisa Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health; 2017;5:e1192\u2013e1207. Available from: \n                    https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3\n                    \n                  . The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license","journal-title":"The Lancet Global Health"},{"key":"298_CR8","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis c virus infection","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis c virus infection. Geneva: WHO; 2018."},{"key":"298_CR9","doi-asserted-by":"publisher","first-page":"C45","DOI":"10.1016\/j.vaccine.2012.02.021","volume":"30","author":"Rosemary J. Burnett","year":"2012","unstructured":"Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine. 2012;30:C45\u201351. Available from: \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.021\n                    \n                  .","journal-title":"Vaccine"},{"key":"298_CR10","volume-title":"Consolidated guidelines on HIV testing services","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Consolidated guidelines on HIV testing services. Geneva: WHO; 2015."},{"key":"298_CR11","unstructured":"World Health Organization. Guidelines on hepatitis B and C testing. Geneva: WHO; 2017. Available from: \n                    https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254621\/9789241549981-eng.pdf?sequence=1\n                    \n                  ."},{"issue":"9737","key":"298_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0140-6736(10)60743-X","volume":"376","author":"Steffanie A Strathdee","year":"2010","unstructured":"Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376:268\u201384. Available from: \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)60743-X\n                    \n                  . [cited 2012 Mar 9].","journal-title":"The Lancet"},{"key":"298_CR13","first-page":"197","volume":"20","author":"A Scheibe","year":"2017","unstructured":"Scheibe A, Shelly S, Versfeld A, Howell S, Marks M. Safe treatment and treatment of safety: call for a harm-reduction approach to drug-use disorders in South Africa. South African Heal Rev. 2017;20:197\u2013204.","journal-title":"South African Heal Rev"},{"key":"298_CR14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.7196\/SAMJ.2017.v107i12.12623","volume":"107","author":"NP Semugoma","year":"2017","unstructured":"Semugoma NP, Rebe K, Sonderup MW, Kamkeumah M, De Swardt G, Struthers H, et al. Hepatitis C: a South African literature review and results from a burden of disease study among a cohort of drug-using men who have sex with men in Cape Town, South Africa. S Afr Med J. 2017;107:1116\u201320.","journal-title":"S Afr Med J"},{"key":"298_CR15","doi-asserted-by":"crossref","unstructured":"Scheibe A, Shelly S, Lambert A, Schneider A, Basson R, Medeiros N, et al. Using a programmatic mapping approach to plan for HIV prevention and harm reduction interventions for people who inject drugs in three South African cities. Harm Reduct J. Harm Reduct J. 2017;14:35. Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5463380\/pdf\/12954_2017_Article_164.pdf\n                    \n                  .","DOI":"10.1186\/s12954-017-0164-z"},{"key":"298_CR16","first-page":"800","volume-title":"Developing an advocacy agenda for increasing access to opioid substitution therapy as part of comprehensive services for people who use drugs in South Africa","author":"A Scheibe","year":"2018","unstructured":"Scheibe A, Marks M, Shelly S, Gerardy T, Domingo A, Hugo J. Developing an advocacy agenda for increasing access to opioid substitution therapy as part of comprehensive services for people who use drugs in South Africa, vol. 108; 2018. p. 800\u20132."},{"issue":"1","key":"298_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7517-10-13","volume":"10","author":"Zaino Petersen","year":"2013","unstructured":"Petersen Z, Myers B, van Hout M-C, Pl\u00fcddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J. 2013;10:13. Available from: \n                    https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/1477-7517-10-13\n                    \n                  . [cited 2013 Aug 26].","journal-title":"Harm Reduction Journal"},{"key":"298_CR18","unstructured":"UNAIDS. Do no harm. Health, human rights and people who use drugs. Report. Geneva: UNAIDS; 2016. Available from: \n                    http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/donoharm_en.pdf\n                    \n                  ."},{"key":"298_CR19","unstructured":"South African National AIDS Council: Key Populations Cascades Stakeholder Group. 2018. Report of the South African Key Populations Cascades Stakeholder Group Workshop. Summary and Recommendations from February 2018 workshop. Pretoria: SANAC; 2018."},{"key":"298_CR20","unstructured":"South African Medical Research Council. South African community epidemiology network on drug use. SACENDU reports 1998 - 2016. Available from: \n                    http:\/\/www.mrc.ac.za\/intramural-research-units\/ATOD-sacendu\n                    \n                  . Accessed 1 Sept 2018."},{"key":"298_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2016.01.004","volume":"30","author":"A Scheibe","year":"2016","unstructured":"Scheibe A, Makapela D, Brown B, Santos M, Hariga F, Virk H. HIV prevalence and risk among people who inject drugs in five South African cities. Int J Drug Policy. 2016;30:107 Available from: \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2016.01.004\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"298_CR22","volume-title":"Viral hepatitis sceening","author":"Sediba Hope Medical Centre","year":"2013","unstructured":"Sediba Hope Medical Centre. Viral hepatitis sceening. Pretoria: Sediba Hope Medical Centre; 2013."},{"key":"298_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","volume":"2","author":"MW Sonderup","year":"2017","unstructured":"Sonderup MW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol Hepatol. 2017;2:910\u20139 Available from: \n                    https:\/\/doi.org\/10.1016\/S2468-1253(17)30249-2\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"298_CR24","unstructured":"South African National AIDS Council (SANAC). Key Populations Cascade Stakeholder Group. Reports of the South African key populations stakeholder group workshop: February 2018. Pretoria: SANAC; 2018."},{"issue":"3","key":"298_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.drugalcdep.2013.03.009","volume":"132","author":"Sabriya L. Linton","year":"2013","unstructured":"Linton SL, Celentano DD, Kirk GD, Mehta SH. The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. Drug Alcohol Depend. 2013;132:457\u201365. Available from: \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.03.009\n                    \n                  .","journal-title":"Drug and Alcohol Dependence"},{"key":"298_CR26","first-page":"1","volume-title":"Every single person looks at us bad","author":"S Shelly","year":"2017","unstructured":"Shelly S, Broughton I, Mcbide A, van Hofmeyer Z, Medeiros N, van Staden C, et al. Every single person looks at us bad. Cape Town: South African Network of People Who Use Drugs; 2017. p. 1\u201343."},{"key":"298_CR27","unstructured":"TB HIV Care Association. Step Up Project. Human rights violations report 2017. Cape Town: TB HIV Care Association; 2017. Available from: \n                    http:\/\/www.stepupprojectsouthafrica.org\/"},{"key":"298_CR28","unstructured":"Scheibe A, Lambert A, Schneider A, Shelly S, Basson R, Medeiros N, et al. Using programmatic mapping to identify locations where people who inject drugs congregate and to estimate their population sizes in three South African cities. In: 21st International AIDS Conference. Poster Presentation THPEES90. Durban: IAS; 2016."},{"issue":"9","key":"298_CR29","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","volume":"17","author":"Abu S. Abdul-Quader","year":"2013","unstructured":"Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, Horvath T, Kennedy GE, Des Jarlais DC. Effectiveness of Structural-Level Needle\/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review. AIDS Behav. 2013;17(9):2878-92. \n                    http:\/\/chipts.ucla.edu\/wp-content\/uploads\/2015\/07\/Effectiveness-of-Structural-Level-Needle-Syringe-Programs-to-Reduce-HCV-and-HIV-Infection-Among-People-Who-Inject-Drugs-A-Systematic-Review.pdf\n                    \n                  .","journal-title":"AIDS and Behavior"},{"key":"298_CR30","doi-asserted-by":"crossref","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;2017:CD012021. Available from: \n                    https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012021.pub2\/full\n                    \n                  .","DOI":"10.1002\/14651858.CD012021.pub2"},{"key":"298_CR31","volume-title":"Kenya the impact of prevention and treatment interentions for PWID in East Africa. Presentation","author":"P Vickerman","year":"2018","unstructured":"Vickerman P, Stone J, Walker J. Kenya the impact of prevention and treatment interentions for PWID in East Africa. Presentation. Brisol: University of Brisol; 2018."},{"issue":"7","key":"298_CR32","doi-asserted-by":"publisher","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","volume":"9","author":"Lucas Wiessing","year":"2014","unstructured":"Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. Khudyakov YE, editor. PLoS One. 2014;9:e103345. Available from: \n                    https:\/\/doi.org\/10.1371\/journal.pone.0103345\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"298_CR33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jhep.2016.07.042","volume":"65","author":"G Robaeys","year":"2016","unstructured":"Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. European Association for the Study of the. Liver. 2016;65:1094\u2013103 Available from: \n                    https:\/\/doi.org\/10.1016\/j.jhep.2016.07.042\n                    \n                  .","journal-title":"Liver"},{"issue":"11","key":"298_CR34","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/jvh.12571","volume":"23","author":"N. Prabdial-Sing","year":"2016","unstructured":"Prabdial-Sing N, Chirwa T, Thaver J, Smuts H, Vermeulen M, Suchard M, et al. Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012. J Viral Hepat. 2016;23:881\u20138. Available from: \n                    https:\/\/doi.org\/10.1111\/jvh.12571\n                    \n                  .","journal-title":"Journal of Viral Hepatitis"},{"key":"298_CR35","first-page":"1","volume-title":"Monitoring alcohol, tobaccoe and other drug use trends in South Africa. Phase 43","author":"South African Community Epidemiology Network on Drug Use","year":"2018","unstructured":"South African Community Epidemiology Network on Drug Use. Monitoring alcohol, tobaccoe and other drug use trends in South Africa. Phase 43. Cape Town: South African Medical Research Council; 2018. p. 1\u201368."},{"key":"298_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09581596.2018.1443204","volume":"1596","author":"A Versfeld","year":"2018","unstructured":"Versfeld A, Scheibe A, Shelly S, Wildschut J, Versfeld A, Scheibe A, et al. Empathic response and no need for perfection: reflections on harm reduction engagement in South Africa. Crit Public Health. 2018;1596:1\u201311 Available from: \n                    https:\/\/doi.org\/10.1080\/09581596.2018.1443204\n                    \n                  .","journal-title":"Crit Public Health"},{"key":"298_CR37","volume-title":"Women who use drugs in Kenya: the needs of female drug users","author":"M Carriere","year":"2016","unstructured":"MEWA, Reach Out Trust, The Omari Project, Carriere M, Essink L. Women who use drugs in Kenya: the needs of female drug users. Amsterdam: Mainline; 2016."},{"issue":"12","key":"298_CR38","doi-asserted-by":"publisher","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"Sarah Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5:1\u201313. Available from: \n                    https:\/\/doi.org\/10.1016\/S2214-109X(17)30373-X\n                    \n                  . The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.","journal-title":"The Lancet Global Health"},{"issue":"1","key":"298_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"Magdalena Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7. Available from: \n                    https:\/\/doi.org\/10.1186\/1477-7517-10-7\n                    \n                  .","journal-title":"Harm Reduction Journal"},{"key":"298_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drugpo.2016.01.012","volume":"30","author":"Sophia Zamudio-Haas","year":"2016","unstructured":"Zamudio-Haas S, Mahenge B, Saleem H, Mbwambo J, Lambdin BH. Generating trust: programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania. Int J Drug Policy. 2016;30:43\u201351. Available from: \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2016.01.012\n                    \n                  .","journal-title":"International Journal of Drug Policy"},{"key":"298_CR41","unstructured":"Statistics South Africa. Mid-year population estimates 2018. Pretoria: Statistics South Africa; 2018. Available from: \n                    https:\/\/www.statssa.gov.za\/publications\/P0302\/P03022018.pdf\n                    \n                  ."},{"key":"298_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2018.05.030","volume":"190","author":"L Briand Madrid","year":"2018","unstructured":"Briand Madrid L, Morel S, Ndiaye K, Mezaache S, Rojas Castro D, Mora M, et al. Factors associated with perceived loss of libido in people who inject opioids: results from a community-based survey in France. Drug Alcohol Depend. 2018;190:121\u20137 Available from: \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.05.030\n                    \n                  .","journal-title":"Drug Alcohol Depend"},{"key":"298_CR43","doi-asserted-by":"publisher","first-page":"e109282","DOI":"10.1371\/journal.pone.0109282","volume":"9","author":"MD Morris","year":"2014","unstructured":"Morris MD, Evans J, Montgomery M, Yu M, Briceno A, Page K, et al. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One. 2014;9:e109282.","journal-title":"PLoS One"},{"issue":"1","key":"298_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1363459316660859","volume":"22","author":"Jake Rance","year":"2016","unstructured":"Rance J, Rhodes T, Fraser S, Bryant J, Treloar C. Practices of partnership: negotiated safety among couples who inject drugs. Heal An Interdiscip J Soc Study Heal Illn Med. 2018;22:3\u201319. Available from: \n                    https:\/\/doi.org\/10.1177\/1363459316660859\n                    \n                  .","journal-title":"Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine"},{"key":"298_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.drugalcdep.2015.09.025","volume":"156","author":"Meghan D. Morris","year":"2015","unstructured":"Morris MD, Bates A, Andrew E, Hahn J, Page K, Maher L. More than just someone to inject drugs with: injecting within primary injection partnerships. Drug Alcohol Depend. 2015;156:275\u201381. Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4633359\/pdf\/nihms730583.pdf\n                    \n                  .","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0298-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0298-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0298-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T23:38:01Z","timestamp":1586475481000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0298-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0298-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Human Research Ethics Committee of the University of Cape Town (ref: 004\/2016), the Research Ethics Committee of the University of the Witwatersrand (ref: M160510) and the Western Cape (ref: WC_2016RP19_818) and KwaZulu-Natal (ref: KZN_2016RP59_986) Provincial Department of Health Ethics Committees. All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS: is a faculty member of the Bristol-Myers Squibb Foundation and has received an honorarium from Gilead Pharmaceuticals to present hepatitis prevalence data at a South African conference for HIV clinicians.KY: No competing interestsLM: No competing interestsRB: No competing interestsAV: No competing interestsCWS: No competing interestsMS: No competing interestsKR: No completing interestsNPS: No competing interestsJM: No competing interestsAP: No competing interestsHH: No competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"28"}}